A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.

Trial Profile

A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs CDX-0158 (Primary)
  • Indications Gastrointestinal stromal tumours; Solid tumours
  • Focus Adverse reactions
  • Sponsors Celldex Therapeutics; Kolltan Pharmaceuticals
  • Most Recent Events

    • 10 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Mar 2017 Data from the study are expected by year-end 2017, as reported in Celldex Therapeutics media release
    • 04 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top